Latest news with #CohanceLifesciencesLimited
Time of India
4 days ago
- Business
- Time of India
Cohance to invest Rs 110 crore in new facilities in Hyderabad and New Jersey
Hyderabad: Cohance Lifesciences Limited, backed by PE giant Advent International, is investing Rs 110 crore in its facilities in Hyderabad and New Jersey. This includes $10 million (approx. Rs 87 crore) in expanding its cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, and Rs 23 crore in its new cGMP oligonucleotide building block manufacturing facility in Hyderabad. The new facility in Hyderabad, Cohance said, will enable it to take high-value chemistries like modified nucleosides and locked nucleic acids (LNA) from laboratory scale to full commercial manufacturing to fulfil the needs of innovators advancing oligonucleotide-based therapeutics. The Hyderabad-based company mentioned that the Hyderabad plant, integrated with a pilot plant for early-stage synthesis and non-GMP scale-up, will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad | Gold Rates Today in Hyderabad | Silver Rates Today in Hyderabad The company said the US investment will significantly enhance its capabilities to deliver fully integrated antibody-drug conjugate (ADC) solutions. The strategic investment in Hyderabad will strengthen its integrated oligonucleotide platform and boost its prospects as a preferred partner for emerging modalities by enhancing its ability to support innovators from early development through late-phase clinical supply. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Once back of the pack, Chinese running shoes now look to surge ahead in S'pore market CNA Read More Undo The two investments are part of its planned capacity expansion programme across high-growth modalities, which would enhance its ability to serve global innovators from early development to commercial supply, the company said. Cohance Lifesciences Executive Chairman Vivek Sharma said: "Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics. " Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Hans India
5 days ago
- Business
- Hans India
Cohance Lifesciences Announces ₹230 mn Investment and Progress on cGMP Oligonucleotide Facility at Hyderabad, India
Cohance Lifesciences Limited ('Cohance' or 'the Company'), a partner of choice for global innovator pharma companies, announced INR 230 million investment and significant progress on its new cGMP oligonucleotide building block manufacturing facility in Hyderabad, India. This strategic investment strengthens Cohance's integrated oligonucleotide platform and enhances its position as a preferred partner for emerging modalities. Cohance brings deep expertise in modified nucleosides and locked nucleic acids (LNA), with a proven track record in complex nucleoside and nucleic acid synthesis at the R&D stage. The new facility will enable the Company to take these high-value chemistries from laboratory scale to full commercial manufacturing, meeting the needs of innovators advancing oligonucleotide-based therapeutics. Integrated with pilot plant for early-stage synthesis and for non-GMP scale-up, the facility will add fit-for-purpose GMP capacity of up to 700 kg annually, with room for future expansion. This scale, combined with advanced environmental controls including ISO Class 8 clean rooms and RH-controlled areas, is designed to meet the stringent requirements of complex oligonucleotide building block production. Customer engagements are already underway, with audits planned in the coming quarters. Kilo lab validations and modified nucleotides are in progress, with GMP-grade PMO and LNA amidite validations expected to commence in CY26. Vivek Sharma, Executive Chairman, Cohance Lifesciences, said: 'Oligonucleotides are a fast-emerging therapeutic class, and innovators are seeking integrated, cost-efficient partners with scalable GMP capacity. This facility is a high-impact strategic investment that complements our pilot and scale-up assets, positioning Cohance to deliver with speed, quality, and flexibility while expanding our role in next-generation therapeutics.' This investment follows the Company's recently announced USD 10 million expansion of cGMP bioconjugation capabilities at NJ Bio in the United States. Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply.
Economic Times
22-05-2025
- Business
- Economic Times
Exploring the Growth Potential of the Indian Pharmaceutical Sector
Sector Performance and Outlook Top Companies Analysts Recommend Based on Upside Potential Company Name Current Price Target Price Upside Potential Recommendation Cohance Lifesciences Limited Rs. 1065.4 Rs. 1400.00 33% Strong Buy Piramal Pharma Rs. 205.74 Rs. 271.00 32% Strong Buy Natco Pharma Rs. 870.1 Rs. 1090.00 28% Hold Aurobindo Pharma Rs. 1182 Rs. 1470.00 23% Buy Blue Jet Healthcare Rs. 794.3 Rs. 943.00 19% Buy Zydus Lifesciences Rs. 906.65 Rs. 1040.00 18% Hold Cohance Lifesciences Live Events Piramal Pharma Natco Pharma Aurobindo Pharma Blue Jet Healthcare Zydus Lifesciences (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The Indian pharmaceutical sector has demonstrated a robust growth trajectory, with a notable increase in performance over the past year. The sector has benefitted from a new trade agreement with the European Union, which aims to reduce tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic medicines , leading to increased trade volume and job creation within the the short term, the sector has shown positive momentum, reflecting a steady rise in investor confidence. The long-term implications of the trade agreement include improved access to European markets and potential technology transfer, which could significantly bolster India's pharmaceutical innovation capabilities. Overall, the outlook for the sector remains positive, with analysts projecting substantial upside potential for various companies operating within this space. Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, is a technology-driven contract development and manufacturing organization(CDMO)based in India. The company specializes in providing integrated solutions in custom synthesis, process research and development, and manufacturing. Its business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient(API) have a strong buy recommendation for Cohance Lifesciences, with a target price of Rs. 1400.00, indicating an upside potential of 33%. The company has shown impressive financial performance, with a year-on-year PAT growth of 77.27%, despite a slight decline in sales growth of 21.56%. Piramal Pharma Limited is a global pharmaceutical company offering a diverse portfolio of differentiated pharma products across a domestic and global distribution network. The company operates approximately 17 development and manufacturing facilities across India, the UK/Europe, and North a strong buy recommendation from analysts, Piramal Pharma has a target price of Rs. 271.00, reflecting an upside potential of 32%. The latest financial data shows a sales growth of 11.99% year-on-year, although the PAT stands at Rs. 153.5 Cr. Natco Pharma Limited is an India-based vertically integrated pharmaceutical company focused on research and development. The company specializes in developing, manufacturing, and commercializing complex pharmaceuticals targeting specific therapeutic recommend holding Natco Pharma, with a target price of Rs. 1090.00, indicating an upside potential of 28%. The latest financial results reveal a significant year-on-year sales growth of 47.72%, although PAT has decreased by 37.47% compared to the previous year. Aurobindo Pharma Limited is engaged in the manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company has a global presence, marketing its products in approximately 150 a buy recommendation from analysts, Aurobindo Pharma has a target price of Rs. 1470.00, reflecting an upside potential of 23%. The company reported a year-on-year sales growth of 16.68%, although PAT has decreased by 9.66% in the latest quarter. Blue Jet Healthcare Limited specializes in manufacturing integrated contrast media, artificial sweeteners, and niche pharmaceutical intermediaries. The company operates primarily as a business-to-business entity, serving various industries have a buy recommendation for Blue Jet Healthcare, with a target price of Rs. 943.00, indicating an upside potential of 19%. The company has demonstrated remarkable financial growth, with a year-on-year PAT growth of 177.64% and sales growth of 44.74%. Zydus Lifesciences Limited is a global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company has a diverse product portfolio, including active pharmaceutical ingredients and human recommend holding Zydus Lifesciences, with a target price of Rs. 1040.00, reflecting an upside potential of 18%. The company has reported a year-on-year sales growth of 18.9%, although PAT has decreased by 5.79% in the latest quarter.
Time of India
22-05-2025
- Business
- Time of India
Exploring the Growth Potential of the Indian Pharmaceutical Sector
Sector Performance and Outlook The Indian pharmaceutical sector has demonstrated a robust growth trajectory, with a notable increase in performance over the past year. The sector has benefitted from a new trade agreement with the European Union, which aims to reduce tariffs on key drug exports. This agreement is expected to enhance India's position as a global supplier of generic medicines , leading to increased trade volume and job creation within the sector. In the short term, the sector has shown positive momentum, reflecting a steady rise in investor confidence. The long-term implications of the trade agreement include improved access to European markets and potential technology transfer, which could significantly bolster India's pharmaceutical innovation capabilities. Overall, the outlook for the sector remains positive, with analysts projecting substantial upside potential for various companies operating within this space. Top Companies Analysts Recommend Based on Upside Potential Company Name Current Price Target Price Upside Potential Recommendation Cohance Lifesciences Limited Rs. 1065.4 Rs. 1400.00 33% Strong Buy Piramal Pharma Rs. 205.74 Rs. 271.00 32% Strong Buy Natco Pharma Rs. 870.1 Rs. 1090.00 28% Hold Aurobindo Pharma Rs. 1182 Rs. 1470.00 23% Buy Blue Jet Healthcare Rs. 794.3 Rs. 943.00 19% Buy Zydus Lifesciences Rs. 906.65 Rs. 1040.00 18% Hold Cohance Lifesciences Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, is a technology-driven contract development and manufacturing organization(CDMO)based in India. The company specializes in providing integrated solutions in custom synthesis, process research and development, and manufacturing. Its business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient(API)services. Analysts have a strong buy recommendation for Cohance Lifesciences, with a target price of Rs. 1400.00, indicating an upside potential of 33%. The company has shown impressive financial performance, with a year-on-year PAT growth of 77.27%, despite a slight decline in sales growth of 21.56%. Piramal Pharma Piramal Pharma Limited is a global pharmaceutical company offering a diverse portfolio of differentiated pharma products across a domestic and global distribution network. The company operates approximately 17 development and manufacturing facilities across India, the UK/Europe, and North America. With a strong buy recommendation from analysts, Piramal Pharma has a target price of Rs. 271.00, reflecting an upside potential of 32%. The latest financial data shows a sales growth of 11.99% year-on-year, although the PAT stands at Rs. 153.5 Cr. Natco Pharma Natco Pharma Limited is an India-based vertically integrated pharmaceutical company focused on research and development. The company specializes in developing, manufacturing, and commercializing complex pharmaceuticals targeting specific therapeutic areas. Analysts recommend holding Natco Pharma, with a target price of Rs. 1090.00, indicating an upside potential of 28%. The latest financial results reveal a significant year-on-year sales growth of 47.72%, although PAT has decreased by 37.47% compared to the previous year. Aurobindo Pharma Aurobindo Pharma Limited is engaged in the manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, and generic pharmaceuticals. The company has a global presence, marketing its products in approximately 150 countries. With a buy recommendation from analysts, Aurobindo Pharma has a target price of Rs. 1470.00, reflecting an upside potential of 23%. The company reported a year-on-year sales growth of 16.68%, although PAT has decreased by 9.66% in the latest quarter. Blue Jet Healthcare Blue Jet Healthcare Limited specializes in manufacturing integrated contrast media, artificial sweeteners, and niche pharmaceutical intermediaries. The company operates primarily as a business-to-business entity, serving various industries globally. Analysts have a buy recommendation for Blue Jet Healthcare, with a target price of Rs. 943.00, indicating an upside potential of 19%. The company has demonstrated remarkable financial growth, with a year-on-year PAT growth of 177.64% and sales growth of 44.74%. Zydus Lifesciences Zydus Lifesciences Limited is a global life sciences company engaged in discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The company has a diverse product portfolio, including active pharmaceutical ingredients and human formulations. Analysts recommend holding Zydus Lifesciences, with a target price of Rs. 1040.00, reflecting an upside potential of 18%. The company has reported a year-on-year sales growth of 18.9%, although PAT has decreased by 5.79% in the latest quarter.
Business Upturn
09-05-2025
- Business
- Business Upturn
Suven Pharma allots 12.8 crore shares under merger with Cohance; company renamed as Cohance Lifesciences
By News Desk Published on May 9, 2025, 09:24 IST Suven Pharmaceuticals Limited, now renamed Cohance Lifesciences Limited, has announced the allotment of 12,80,02,184 equity shares as part of its approved Scheme of Amalgamation with Cohance Lifesciences, the company said in a regulatory filing on May 9. The allotment follows the order from the National Company Law Tribunal (NCLT), Mumbai bench, dated March 27, 2025, approving the merger under Sections 230 to 232 of the Companies Act, 2013. As per the share exchange ratio detailed in the scheme, eligible shareholders of Cohance (Transferor Company) have received 11 equity shares of Re. 1 each of Suven Pharma (Transferee Company) for every 295 equity shares of ₹10 each held in the transferor company. The newly issued shares will be listed and traded on the BSE and NSE, and will rank pari-passu with the existing equity shares of the company. As part of the allotment, the company has also: Allotted 18 equity shares to a Fractional Share Demat Account, to accommodate fractional entitlements. Allotted 34,906 shares to an Unclaimed Securities – Suspense Escrow Account, representing shares of eligible shareholders whose individual demat details were unavailable as of the record date. The company had previously intimated the exchanges on May 7 about its official name change to Cohance Lifesciences Limited, following approval from the Ministry of Corporate Affairs. News desk at
